

JAGADISHWAR

PHARMACEUTICAL WORKS LIMITED

CIN : L24232AS1987PLC002803

Regd. Off.: 205, Haribol Roy Market, 2nd Floor, A.T.Road, Guwahati -781001

Corp. Off.: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E_mail ID: jpwltd@yahoo.com

Phone No.: +91 9163513015

Date: August 9, 2022

**Head- Listing & Compliance
Metropolitan Stock Exchange of India Ltd. (MSEI),
4th Floor, Vibgyor Towers, Plot No. C 62,
G Block, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 098**

Dear Sir,

Sub: Outcome of the Board Meeting held on today, 9th August 2022

Please note that the Board of Directors of the Company at its meeting held today, which commenced at 2.45 p.m. and concluded at 3.15 p.m. as inter alia transacted the following business (es):

1. Considered, approved and adopted the Un-audited Financial Results for the quarter ended 30th June, 2022. A copy of Un-audited Financial Results for the quarter ended 30th June, 2022 alongwith Limited Review Report of the Company is enclosed;

Kindly take the same on your record and oblige.

Thanking You,

For Jagadishwar Pharmaceutical Works Limited



**Swapan Sarkar
Director
DIN: 05149442**

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email ID: jpw ltd@yahoo.com **Website:** jagadishwarpharma.com **Tel:** +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022


(Rupees In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.22	31.03.22	30.06.21	31.03.22
		Unaudited	Audited	Unaudited	Audited
PART - I					
I	Income From Operations	-	-	-	1.85
II	Other Income	11.01	11.45	14.23	50.70
III	Total Income from operations (I + II)	11.01	11.45	14.23	52.55
IV	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	3.04
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	(1.19)
	(d) Employee benefits expense	5.13	4.94	4.58	20.19
	(e) Depreciation and amortisation expense	-	-	-	-
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	4.57	2.15	4.67	10.81
	Total Expenses	9.70	7.08	9.25	32.85
V	Profit (Loss) before exceptional Items and extraordinary items and tax (III-IV)	1.31	4.37	4.99	19.70
VI	Exceptional Items	-	-	6.84	6.84
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	1.31	4.37	(1.86)	12.85
VIII	Extra Ordinary Items	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	1.31	4.37	(1.86)	12.85
X	Tax Expense :				
	(1) Current Tax	1.10	(0.52)	1.42	3.40
	(2) Deferred Tax	-	-	-	-
	Total Tax Expenses	1.10	(0.52)	1.42	3.40
XI	Net profit /(Loss) for the period from continuing operations (IX-X)	0.21	4.89	(3.28)	9.45
XII	Profit /(Loss) for the period from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit /(Loss) for the period from discontinuing operations (after tax)	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	0.21	4.89	(3.28)	9.45
XVI	Other Comprehensive Income	-	(6.37)	-	(6.37)
XVII	Total Comprehensive Income	0.21	(1.48)	(3.28)	3.08
XVIII	Paid up equity share capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02
XVIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	112.66
XX	Earnings Per Share (EPS)				
	(a) Basic	-	0.02	-	0.03
	(b) Diluted	-	0.02	-	0.03

Notes :

- 1 The figures for the corresponding previous periods have been restated / regrouped, wherever necessary, to make them comparable.
- 2 These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable .
- 3 The Audit Committee reviewed the above results. The Board of Directors at its meeting held on 09th August, 2022, approved the above results. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 4 The Company does not have any reportable segment as per Indian Accounting Standard "Operating Segment" (Ind AS 108) Accordingly,

For Jagadishwar Pharmaceuticals Works Ltd.



Mr. Swapan Sarkar
Director

(DIN : 05149442)

Date : 09/08/2022

Place: Guwahati

LIMITED REVIEW REPORT

To

The Board of Directors,

Jagadishwar Pharmaceutical Works Limited

CIN : L24232AS1987PLC002803

We have reviewed the unaudited financial results of **Jagadishwar Pharmaceutical Works Limited** (“the Company”), for the quarter ended June 30, 2022 together with the notes thereon (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), Which has been initialed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company’s opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim financial information performed by the independent auditor of the entity” issues by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practiced and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to the following matters:

- a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2022, and accordingly, the Statement has been prepared by the Company’s Management in compliance with Ind AS.
- b) We were neither engaged to review, nor have we review, nor have we reviewed the comparative figures including reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2022. As set out in note 5 to the Statement, these figures have been furnished by the Management.

Place : Kolkata

Date : 9th August, 2022

UDIN : 22016230AOPFEL3628



For **S. N. Chakrabarty & Co.**
Chartered Accountants

Saurindra Nath Chakrabarty
(Proprietor)

Membership No : 016230

Firm Regn. No.: 309080E